secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0000950170-24-043347
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics CFO departs; Bryant Lim named interim CFO
--------------------------------------------------------------

- Laurent Chardonnet ceased as CFO on April 8, 2024; he will consult at $500/hr through Oct 4, 2024.
- Bryant D. Lim, current Chief Legal Officer and Secretary, appointed interim CFO.
- Chardonnet receives severance of $333,750 (9 months base salary) plus COBRA subsidy.
- Consulting fee up to $50,000; Chardonnet's equity awards continue vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024043347/0000950170-24-043347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017024043347/prld-20240408.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-043347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer